X-Therma Inc., a Richmond, Calif.-based biotechnology company developing technology for regenerative medicine and organ preservation, closed a $13M Series A funding round.
The round was led by Lorea AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with angel investors.
The company intends to use the funds to scale commercialization of XT-Thrive®, to expand its multi-disciplinary team, filling positions remotely (both nationally and internationally) in its San Francisco Bay Area headquarters and Austria subsidiary,
Led by Dr. Xiaoxi Wei, CEO & Co-Founder, and Dr. Mark Kline, CTO & Co-founder, X-Therma has developed cold chain technology via a convergent biopreservation platform, to advance Regenerative Medicine and make available safe and on-demand organs, engineered tissues, cell & gene therapies, vaccines, and beyond to patients in need.
X-Therma’s flagship product XT-Thrive®, a DMSO-, Serum-, Protein-free and chemically defined cryopreservation solution directly plugs into the current CMC workflow, resolves bottlenecks in the cell manufacturing process, and enables “off-the-shelf” living medicines.
The company is headquartered in Richmond, part of the San Francisco Bay Area, with research centers in Richmond and Berkeley, and now has expanded to Europe in Austria.